
Vascular endothelial growth factor receptor-2 antagonists - Pipeline Insight, 2024
Description
Vascular endothelial growth factor receptor-2 antagonists - Pipeline Insight, 2024
DelveInsight’s, “Vascular endothelial growth factor receptor-2 antagonists - Pipeline Insight, 2024” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Vascular endothelial growth factor receptor-2 antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Vascular endothelial growth factor receptor-2 antagonists: Overview
Vascular endothelial growth factor receptor-2 (VEGFR-2/KDR/Flk-1) is a high-affinity receptor for vascular endothelial growth factor-A (VEGF-A), and mediates most of the endothelial growth and survival signals from VEGF-A. VEGFR-2 has a typical tyrosine kinase receptor structure with seven immunoglobulin (Ig)-like domains in the extracellular region, as well as a long kinase insert in the tyrosine kinase domain. It utilizes a unique signaling system for DNA synthesis in vascular endothelial cells, i.e. a phospholipase C gamma-protein kinase C-Raf-MAP kinase pathway. Although VEGF-A binds two receptors, VEGFR-1 and -2, a newly isolated ligand VEGF-E (Orf-virus-derived VEGF) binds and activates only VEGFR-2.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Vascular endothelial growth factor receptor-2 antagonists R&D. The therapies under development are focused on novel approaches for Vascular endothelial growth factor receptor-2 antagonists.
This segment of the Vascular endothelial growth factor receptor-2 antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vascular endothelial growth factor receptor-2 antagonists Emerging Drugs
- Nintedanib: Boehringer Ingelheim
- Lenvatinib: Eisai
Further product details are provided in the report……..
Vascular endothelial growth factor receptor-2 antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Vascular endothelial growth factor receptor-2 antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Vascular endothelial growth factor receptor-2 antagonists
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Vascular endothelial growth factor receptor-2 antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Vascular endothelial growth factor receptor-2 antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vascular endothelial growth factor receptor-2 antagonists drugs.
Vascular endothelial growth factor receptor-2 antagonists Report Insights
- Vascular endothelial growth factor receptor-2 antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Vascular endothelial growth factor receptor-2 antagonists drugs?
- How many Vascular endothelial growth factor receptor-2 antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vascular endothelial growth factor receptor-2 antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vascular endothelial growth factor receptor-2 antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Vascular endothelial growth factor receptor-2 antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- Boehringer Ingelheim
- Eisai
- Advenchen Laboratories
- AiViva BioPharma
- Deciphera Pharmaceuticals
- Mirati Therapeutics
- HUTCMED
- Pfizer
- Aerie Pharmaceuticals
- Xspray Pharma
- Ascendis Pharma
- Lynkcell
- PharmAbcine
- Jiangsu Hengrui Medicine
- Chipscreen Biosciences
- Ocular Therapeutix
- Roche
- Bayer
- Metagone Biotech
- Bristol-Myers Squibb
- Akeso Biopharma
- Clearside Biomedical
- ZAI Lab
- Wayshine Biopharma
- Henlix Biotech
- Nintedanib
- Lenvatinib
- Catequentinib
- OTX-TKI
- MG D 1609
- BAY-57-9352
- Lucitanib
- ZL-2301
- HLX06
- WSD 1227
- Pazopanib intravitreal
- AK 109
- CS-2164
- CLS 1002
- AIV 007
- SHR 1020
- Ripretinib
- Sitravatinib
- Olinvacimab
- LYN 00101
- TransCon VEGF-TKI
- Surufatinib
- Axitinib
- Axitinib implant
- Sorafenib nanoparticle formulation
Table of Contents
90 Pages
- Introduction
- Executive Summary
- Vascular endothelial growth factor receptor-2 antagonists: Overview
- Structure
- Mechanism of Action
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Vascular endothelial growth factor receptor-2 antagonists – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Nintedanib: Boehringer Ingelheim
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- ZL-2301: ZAI Lab
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Lenvatinib - AiViva BioPharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- Comparative Analysis
- TransCon VEGF-TKI: Ascendis Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Vascular endothelial growth factor receptor-2 antagonists Key Companies
- Vascular endothelial growth factor receptor-2 antagonists Key Products
- Vascular endothelial growth factor receptor-2 antagonists- Unmet Needs
- Vascular endothelial growth factor receptor-2 antagonists- Market Drivers and Barriers
- Vascular endothelial growth factor receptor-2 antagonists- Future Perspectives and Conclusion
- Vascular endothelial growth factor receptor-2 antagonists Analyst Views
- Vascular endothelial growth factor receptor-2 antagonists Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.